ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals reported Q2 2026 total net revenues of $266.0 million, up 25.9% year over year, and adjusted non-GAAP EBITDA of $71.6 million, up 32.4%. Cortrophin Gel revenues were $117.1 million (+43.5%). 2026 guidance: net revenue $1.08B-$1.14B, Cortrophin Gel $520M-$540M, adjusted EBITDA $285M-$300M, EPS $9.19-$9.69.
How this was made
The 30-second read
Why it matters
Traders can update models for 2026 revenue, EBITDA, EPS, and segment mix, with particular attention to the narrowed Cortrophin Gel range and the timing of remaining Harmony milestone recognition in Q3 2026.
Market read
This is a company-specific earnings call transcript with quantified guidance changes and execution metrics that can drive near-term estimate revisions.
What to watch
ILUVIEN revenue declined due to shipment timing, and gross margin guidance reflects mix shift toward royalty-bearing items, which could cap profitability despite revenue growth.
Background
ANI is transitioning toward a rare-disease focus, with Cortrophin Gel as a key growth driver and Harmony Biosciences contributing royalties and development milestones.
Ticker impact
ANI reported Q2 results and updated 2026 guidance, including narrowed Cortrophin Gel revenue outlook to $520M-$540M.
Moderately positive bias, with upside contingent on Cortrophin Gel demand momentum and delivery of narrowed guidance.
The article discloses multiple quantified updates: Q2 revenue/EPS/EBITDA, full-year revenue and EBITDA guidance, and a specific Cortrophin Gel guidance cut tied to first-half results, plus operational KPIs (new cases, prescriber adoption, sales force ramp).
Market effects
Rare-disease pharma investors may reprice expectations for specialty sales execution and royalty/milestone revenue durability.
No clear regional catalyst beyond US-listed biotech sentiment.
Limited, except for ILUVIEN international shipment timing and the broader rare-disease demand narrative.
Counterpoint
The Cortrophin Gel guidance was lowered versus the prior range, so the market may focus on durability of the first-half shortfall rather than the rare-disease transition story.
Key entities
- issuerANI Pharmaceuticals, Inc.
Reported Q2 2026 results and provided updated 2026 guidance and operational KPIs on its rare-disease and generics segments.
- partnerHarmony Biosciences
Provided royalty and development milestone revenue streams tied to WAKIX royalties and a remaining development milestone expected in Q3 2026.
- productCortrophin Gel
ANI’s rare-disease product whose 2026 revenue guidance was narrowed to $520M-$540M after first-half results.
- productILUVIEN
Sustained-release implant with 2026 net revenue impact described as a year-over-year decline due to international shipment timing.
